(Press-News.org) Researchers at the University of Manchester and Central Manchester University Hospitals NHS Foundation Trust have published data for the first time about public knowledge of and interest in the process of medicines research and development.
The study, which is part of the wider European Patients' Academy on Therapeutic Innovation (EUPATI) project, is believed to be the largest peer-reviewed survey of its kind and was published today in the BMJ Open.
Medicines R&D describes the entire process of bringing a new medicine to patients - from laboratory studies to clinical studies, then regulatory approval and further evaluation during clinical use.
The data, which is segmented by type of medicines R&D (e.g. safety, clinical trials, patients' roles), demographics, country, and level of previous experience in the subject area, will help to improve communications with the public about the field.
By providing an extensive insight into people's knowledge and interests, the researchers hope the data will help drive public involvement in medicines R&D, which is the main objective of the EUPATI project.
Increased engagement and involvement of patients in research has been shown to increase study recruitment/retention and improve patient experience, supporting the delivery of better healthcare through the development of new diagnostics, medicines and devices.
It is thought that the information will also be useful to pharmaceutical companies wishing to involve the public in medicines research.
Dr Lode Dewulf, Chief Patient Affairs Officer at UCB, partner in the project, commented: "We need better studies to answer more relevant questions more efficiently and faster. Collaboration between study sponsors and (future and experienced) study participants is needed for this. But we often lack the required understanding to have such collaboration for all studies. Thus, this survey and its findings greatly contribute to the understanding we need."
A key finding of the EUPATI research, led by Bella Starling, Director of Public Programmes at CMFT, and Kay Warner, Focus on the Patient Manager at GlaxoSmithKline plc, is that those who had previous experience of medical research were almost five times more likely to report having good or very good knowledge of medicines R&D. People also indicated that they are keen to learn more, particularly about medicines safety (50%), and personalised and predictive medicine (47%).
"We are all potential patients," said Kathy Oliver, Co-Chair of EUPATI's Project Advisory Board and Chair of the International Brain Tumour Alliance. "This possibility emphasises the crucial need for the general public to really understand the numerous stages of medicines development and realise the complex processes that take place before a medicine is available for general use. EUPATI's newly-published paper throws a fascinating light on what people already know, and where their learning gaps are. In addition, the paper's findings are of great value to us as patient advocacy groups because they validate the need for organisations like ours to help increase public knowledge and awareness about medicines research and development."
The study which surveyed almost 7,000 people across Europe is part of the European Patients' Academy on Therapeutic Innovation (EUPATI), a patient-led project, which involves a unique European team of academia, patient advocacy organisations and the pharmaceutical industry. EUPATI has been established to provide scientifically reliable, objective, comprehensive information to the public on the research and development process of medicines to both patients and members of the public.
EUPATI is supported by the Innovative Medicines Initiative (IMI), a partnership between the European Union and the European pharmaceutical industry.
Suzanne Parsons, Health Researcher at The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust and lead researcher for the study, explained: "The survey reveals that over 75 percent of respondents had no or less than good knowledge about medicines research. Previous studies have focused on public interest in clinical research, but this is the first time that medicines research has been looked at as a whole and we are able to provide a more holistic view of the subject.
"The data generated through our study will be a powerful tool for the EUPATI project and others who want to engage and involve patients and the public in a specific area of medicines research."
INFORMATION:
Open access paper available here:
http://bmjopen.bmj.com/content/5/4/e006420.full?keytype=ref&ijkey=LJa9LX1il555KeX
The seabed is inhabited by vast numbers of small animals with hidden lives in the sandy sediments. Here they play an important role in keeping the oceans healthy. But how these animals behave and interact with each other is unclear, as it is not possible to see them without disturbing the sediment.
Researchers like Ph.D. Matthieu Delefosse would enjoy putting on a pair of X-ray glasses and study the sediment living animals without disturbing them.
"We know bits and pieces of what these animals do through different measurements/experiments, but we do not have an integrated ...
Researchers at Genes and Cancer group at Bellvitge Biomedical Research Institute (IDIBELL), led by Montse Sanchez-Cespedes, have identified the PARD3 gene as a tumor suppressor that is inactivated in lung cancer squamous type. The results of the study have been published in Cancer Research.
Correct polarization (orientation in space) of bronchial epithelial cells is essential for the maintenance and proper development of this tissue under normal conditions.
PARD3 gene encodes a protein that regulates cell polarization and cell junctions. When the gene is inactivated, ...
Scientists at the University of Sheffield calculate that all of the UK's high level nuclear waste from spent fuel reprocessing could be disposed of in just six boreholes 5km deep, fitting within a site no larger than a football pitch.
The concept - called deep borehole disposal - has been developed primarily in the UK but is likely to see its first field trials in the USA next year. If the trials are successful, the USA hopes to dispose of its 'hottest' and most radioactive waste - left over from plutonium production and currently stored at Hanford in Washington State ...
Simply declaring a region as a nature protection area is not enough, regular monitoring of its ecological condition is also necessary. Since Nature protection areas already cover almost one fifth of the surface of the European Union, it is impossible to inspect such a vast area in the traditional way on foot. Therefore, new methods are being developed to monitor Europe's nature protection areas from the air. Short laser pulses are sent to the ground, and information on the status of the habitat can be deduced from the reflected light signals using elaborate computer algorithms.
Laser ...
Cancer Mortality Reductions Were Greatest Among Countries Where Cancer Care Spending Rose The Most, 1995-2007.
Warren Stevens of Precision Health Economics, Dana P. Goldman of the Schaeffer Center for Health Policy and Economics at the University of Southern California, and coauthors compared cancer care across sixteen countries over time, examining changes in cancer spending and two measures of cancer mortality (amenable and excess mortality). They found that, compared to low-spending health systems, high-spending systems had consistently lower cancer mortality in the ...
Fast Facts:
More than 30,000 people in the U.S. are diagnosed with Lou Gehrig's disease, or amyotrophic lateral sclerosis (ALS).
Johns Hopkins researchers have transformed skin cells donated by ALS patients into brain cells affected by the progressive, fatal disease.
The resulting cell library is being used by researchers worldwide in the quest for better ALS treatments.
Researchers at Johns Hopkins Medicine have transformed skin cells from patients with Lou Gehrig's disease, or amyotrophic lateral sclerosis (ALS), into brain cells affected by the progressive, ...
The World Health Organization (WHO) have announced a new statement on the public disclosure of clinical trial results which updates and expands a previous statement that noted the "the registration of all interventional trials is a scientific, ethical, and moral responsibility." The new statement includes timelines by which researchers are expected to report clinical trials results. In an Essay published in this week's PLOS Medicine Vasee Moorthy and colleagues from the WHO outline the rationale behind the new statement.
A new element in the WHO statement is the definition ...
Extreme hazards - rare, high-impact events - pose a serious and underestimated threat to humanity. The extremes of the broad ensemble of natural and anthropogenic hazards can lead to global disasters and catastrophes. Because they are rare and modern society lacks experience with them, they tend to be ignored in disaster risk management. While the probabilities of most natural hazards do not change much over time, the sensitivity of the built environment and the vulnerability of the embedded socio-economic fabric have increased rapidly. Exposure to geohazards has increased ...
April 14, 2015 A new material developed at the University of Colorado Boulder could radically reduce the energy needed to produce a wide variety of plastic products, from grocery bags and cling wrap to replacement hips and bulletproof vests.
Approximately 80 million metric tons of polyethylene is produced globally each year, making it the most common plastic in the world. An essential building block for manufacturing polyethylene is ethylene, which must be separated from a nearly identical chemical, ethane, before it can be captured and used.
The similarities between ...
Researchers from the RIKEN Center for Emergent Matter Science in Japan have uncovered the first evidence of an unusual quantum phenomenon--the integer quantum Hall effect--in a new type of film, called a 3D topological insulator. In doing this, they demonstrated that "surface Dirac states"--a particular form of massless electrons--are quantized in these materials, meaning that they only take on certain discrete values. These discoveries could help move science forward toward the goal of dissipationless electronics--electronic devices that can operate without producing the ...
